Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Objectives To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. Methods An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. Results The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3–10) days. The median length of stay was 9 (6–14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. Conclusion Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.

[1]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[2]  A. Neimann,et al.  Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York , 2020, The New England journal of medicine.

[3]  Hangyuan Guo,et al.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.

[4]  P. Elkington,et al.  Personal respirators for population level control of the COVID19 pandemic , 2020, Journal of Infection.

[5]  I. Castellví,et al.  Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. , 2020, European journal of rheumatology.

[6]  Theodora Psaltopoulou,et al.  Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.

[7]  Haibo Xu,et al.  Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 , 2020, Journal of Infection.

[8]  C. Hung,et al.  Prolonged virus shedding even after seroconversion in a patient with COVID-19 , 2020, Journal of Infection.

[9]  B. Fernández-Gutiérrez COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause. , 2020, Reumatologia clinica.

[10]  C. Montecucco,et al.  Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.

[11]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England Journal of Medicine.

[12]  R. Cron,et al.  The Rheumatologist’s Role in COVID-19 , 2020, The Journal of Rheumatology.

[13]  D. Galarza-Delgado,et al.  Are my patients with rheumatic diseases at higher risk of COVID-19? , 2020, Annals of the Rheumatic Diseases.

[14]  F. Ingegnoli,et al.  COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.

[15]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[16]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[17]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[18]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[19]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[20]  Michael G. Katze,et al.  Into the Eye of the Cytokine Storm , 2012, Microbiology and Molecular Reviews.

[21]  Jin-Kui Yang,et al.  Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes , 2009, Acta Diabetologica.

[22]  J. Chan,et al.  Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS , 2006, Diabetic medicine : a journal of the British Diabetic Association.